|
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION
Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy.
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
Jindan...
Published: 2/24/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Netrin-1 mimetic peptide amphiphiles
Netrin-1 Mimetic Peptide Amphiphile Assemblies
NU 2024-174
INVENTORS
Samuel Stupp*
Cara Smith
Zaida Alvarez Pinto
SHORT DESCRIPTION
Nanofiber-shaped supramolecular assemblies that mimic netrin-1 bioactivity to stimulate neurite growth and synaptic maturation for enhanced CNS regeneration.
BACKGROUND
Neurotrophic factors are essential for...
Published: 2/20/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, CNS - Central Nervous System, CVA - Cerebrovascular Accident, Nanomaterials, Nanotechnology, Neurodegenerative disease, Regenerative medicine, SCI - Spinal cord injury, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2025-113 (NU 2018-176, NU 2024-250, NU 2025-038)
INVENTORS
Richard Silverman (Weinberg College of Arts and Sciences, Department of Chemistry)
SHORT DESCRIPTION
Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression of nNOS (e.g., gliomas, ovarian cancer)...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Immunotherapy, Melanoma, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081
INVENTORS
Sarki Abdulkadir (PI)*
Gary Schiltz (PI)*
SHORT DESCRIPTION
A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of leukemia and prostate cancer.
BACKGROUND
Current cancer treatments, especially for MLL-rearranged leukemia and prostate cancer, face challenges of off-target effects and...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Leukemia, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Cell-type specific disruption of M1 muscarinic acetylcholine receptor expression to alleviate Parkinson's disease
NU 2024-244
INVENTORS
Dalton J. Surmeier Jr*
Tatiana Tkatch
Shenyu Zhai
SHORT DESCRIPTION
Gene therapy targeting M1 muscarinic receptor expression in striatal spiny projection neurons to enhance levodopa response and slow Parkinson’s Disease progression.
BACKGROUND
Parkinson’s Disease (PD) is the second most common age-related...
Published: 1/5/2026
|
Inventor(s):
Keywords(s): CNS - Central Nervous System, Gene therapy, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Gene therapy for levodopa-induced dyskinesia
NU 2024-086
INVENTORS
Dalton J. Surmeier Jr*
Weixing Shen
Shenyu Zhai
Tatiana Tkatch
Qiaoling Cui
Zhong Xie
SHORT DESCRIPTION
Gene therapy targeting GRIN2B in striatal spiny projection neurons to treat levodopa-induced dyskinesia.
BACKGROUND
Parkinson’s Disease (PD) is the second most common age-related neurodegenerative disease...
Published: 1/5/2026
|
Inventor(s):
Keywords(s): CNS - Central Nervous System, Dyskinesis, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Therapeutic Intervention for ALS and Dementia
NU 2021-058
INVENTORS
Evangelos Kiskinis*
Juan Alberto Ortega Cano Marco Boccitto
SHORT DESCRIPTION
Design of an RNA-based oligonucleotide that protects from dipeptide repeat protein toxicity for the treatment of ALS and FTD.
BACKGROUND
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating neurodegenerative diseases...
Published: 12/18/2025
|
Inventor(s):
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, CNS - Central Nervous System, DPR - Dipeptide Repeat Proteins, FTD - Frontotemporal Dementia, Neurodegenerative disease, Neurology, RNA - Ribonucleic Acid, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
MEK7 inhibitors for acute lymphoblastic leukemia (ALL) treatment
NU 2023-060
INVENTORS
Karl Scheidt*
Dalton Kim
Meghan Orr
SHORT DESCRIPTION
Rational design of highly potent and selective covalent MEK7 inhibitors
BACKGROUND
Acute lymphoblastic leukemia (ALL) is a deadly blood cancer, the most common hematological malignancy in patients under 14 years of age. Despite advancements in treatment, ALL relapse...
Published: 12/16/2025
|
Inventor(s):
Keywords(s): ALL - Acute Lymphoblastic Leukemia, Cancer/Oncology, Leukemia, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Therapy for T-Cell Lymphoma
NU2022-104
INVENTORS
Jaehyuk Choi*
Jay Daniels
Jurgen Ruland
Tim Wartweig
SHORT DESCRIPTION
Targeting PD-1 related mechanisms for treatment of aggressive T-Cell lymphomas
BACKGROUND
T-cell non-Hodgkin lymphomas (T-NHLs) are highly aggressive cancers that can be resistant to chemotherapies. The molecular pathogenesis of these cancers remains...
Published: 12/15/2025
|
Inventor(s):
Keywords(s): Cancer/Oncology, Lymphoma, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Immunomodulatory Nanoparticles for the Therapeutic Intervention of Traumatic Brain Injury
NU 2019-030
INVENTORS
John Kessler
Sripadh Sharma
ABSTRACT
There is no decisive treatment for traumatic brain injury (TBI). After the primary trauma, secondary injury, largely mediated by blood-borne immune cells called monocytes, takes place causing damage to surrounding healthy cells. Furthermore, cellular and whole brain swelling (edema) resulting...
Published: 1/14/2026
|
Inventor(s):
Keywords(s): Autoimmune disease, CNS - Central Nervous System, Immunology, Inflammation, Neurologic disease, Neurology, Targeted therapy, TBI - Traumatic brain injury, Therapeutics
Category(s): Life Sciences > Therapeutics
|